The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery

Neuropharmacology

Volumn 60, Issue 1, 2011, Pages 36-44

  Robertson, Nathan ^a   Jazayeri, Ali ^a   Errey, James ^a   Baig, Asma ^a   Hurrell, Edward ^a   Zhukov, Andrei ^a   Langmead, Christopher J ^a   Weir, Malcolm ^a   Marshall, Fiona H ^a  

^a Heptares Therapeutics Ltd   (United Kingdom)

Author keywords

Drug discovery; G protein coupled receptor; Receptor kinetics; Thermostability

Indexed keywords

ADENOSINE A2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; MUSCARINIC M1 RECEPTOR;

ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PURIFICATION; PROTEIN TARGETING; STRUCTURE ANALYSIS; SURFACE PLASMON RESONANCE; THERMOSTABILITY;

BINDING SITES; CELLS, CULTURED; DRUG DISCOVERY; HEK293 CELLS; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN ENGINEERING; RADIOLIGAND ASSAY; RECEPTOR, ADENOSINE A2A; RECEPTOR, MUSCARINIC M1;

EID: 78149501282     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.07.001     Document Type: Article

References (37)

1. Bokoch M.P., Zou Y., Rasmussen S.G., Liu C.W., Nygaard R., Rosenbaum D.M., Fung J.J., Choi H.J., Thian F.S., Kobilka T.S., Puglisi J.D., Weis W.I., Pardo L., Prosser R.S., Mueller L., Kobilka B.K. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 2010, 463:108-112.
2. Colquhoun D. The Relation between Classical and Cooperative Models for Drug Action 1973, Macmillan Press.
3. Colquhoun D. Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br. J. Pharmacol. 1998, 125:924-947.
4. Comess K.M., Schurdak M.E. Affinity-based screening techniques for enhancing lead discovery. Curr. Opin. Drug Discov. Devel. 2004, 7:411-416.
5. Comess K.M., Schurdak M.E., Voorbach M.J., Coen M., Trumbull J.D., Yang H., Gao L., Tang H., Cheng X., Lerner C.G., McCall J.O., Burns D.J., Beutel B.A. An ultraefficient affinity-based high-throughout screening process: application to bacterial cell wall biosynthesis enzyme MurF. J. Biomol. Screen. 2006, 11:743-754.
6. Congreve M., Marshall F. The impact of GPCR structures on pharmacology and structure-based drug design. Br. J. Pharmacol. 2010, 159:986-996.
7. Conn P.J., Christopoulos A., Lindsley C.W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 2009, 8:41-54.
8. Copeland R.A., Pompliano D.L., Meek T.D. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 2006, 5:730-739.
9. Disse B., Speck G.A., Rominger K.L., Witek T.J., Hammer R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999, 64:457-464.
10. Gether U., Ballesteros J.A., Seifert R., Sanders-Bush E., Weinstein H., Kobilka B.K. Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J. Biol. Chem. 1997, 272:2587-2590.
11. Hegde S., Schmidt M. To market, to market - 2006. Annual Reports in Medicinal Chemistry 2007, vol. 42:505-554. Academic Press, London. J.E. Macor (Ed.).
12. Hornak V., Ahuja S., Eilers M., Goncalves J.A., Sheves M., Reeves P.J., Smith S.O. Light activation of rhodopsin: insights from molecular dynamics simulations guided by solid-state NMR distance restraints. J. Mol. Biol. 2010, 396:510-527.
13. Kapur S., Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry 2001, 158:360-369.
14. Keseru G.M., Makara G.M. The influence of lead discovery strategies on the properties of drug candidates. Nat. Rev. Drug Discov. 2009, 8:203-212.
15. Kobilka B.K., Deupi X. Conformational complexity of G-protein-coupled receptors. Trends Pharmacol. Sci. 2007, 28:397-406.
16. Langmead C.J., Watson J., Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol. Ther. 2008, 117:232-243.
17. Lefkowitz R.J., Mullikin D., Caron M.G. Regulation of beta-adrenergic receptors by guanyl-5'-yl imidodiphosphate and other purine nucleotides. J. Biol. Chem. 1976, 251:4686-4692.
18. Levin V.A. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 1980, 23:682-684.
19. 2a receptor. Proc. Natl. Acad. Sci. U S A 2008, 105:10744-10749.
20. 2A receptors and Parkinson's disease. Handb Exp. Pharmacol. 2009, 589-615.
21. Motulsky H.J., Mahan L.C. The kinetics of competitive radioligand binding predicted by the law of mass action. Mol. Pharmacol. 1984, 25:1-9.
22. Myszka D.G., Rich R.L. Implementing surface plasmon resonance biosensors in drug discovery. Pharm. Sci. Technol. Today 2000, 3:310-317.
23. Navratilova I., Dioszegi M., Myszka D.G. Analyzing ligand and small molecule binding activity of solubilized GPCRs using biosensor technology. Anal. Biochem. 2006, 355:132-139.
24. Paul S.M., Mytelka D.S., Dunwiddie C.T., Persinger C.C., Munos B.H., Lindborg S.R., Schacht A.L. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 2010, 9:203-214.
25. Prive G.G. Detergents for the stabilization and crystallization of membrane proteins. Methods 2007, 41:388-397.
26. Roberts D.J., Strange P.G. Mechanisms of inverse agonist action at D2 dopamine receptors. Br. J. Pharmacol. 2005, 145:34-42.
27. Rosario M.C., Jacqmin P., Dorr P., James I., Jenkins T.M., Abel S., van der Ryst E. Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients. Br. J. Clin. Pharmacol. 2008, 65(Suppl. 1):86-94.
28. Serrano-Vega M.J., Tate C.G. Transferability of thermostabilizing mutations between beta-adrenergic receptors. Mol. Membr. Biol. 2009, 26:385-396.
29. Serrano-Vega M.J., Magnani F., Shibata Y., Tate C.G. Conformational thermostabilization of the b1-adrenergic receptor in a detergent-resistant form. Proc. Natl. Acad. Sci. U S A 2008, 105:877-882.
30. Shibata Y., White J.F., Serrano-Vega M.J., Magnani F., Aloia A.L., Grisshammer R., Tate C.G. Thermostabilization of the neurotensin receptor NTS1. J. Mol. Biol. 2009, 390:262-277.
31. Stephens G.J. G-protein-coupled-receptor-mediated presynaptic inhibition in the cerebellum. Trends Pharmacol. Sci. 2009, 30:421-430.
32. Subramaniam S., Lindahl M., Bullough P., Faruqi A.R., Tittor J., Oesterhelt D., Brown L., Lanyi J., Henderson R. Protein conformational changes in the bacteriorhodopsin photocycle. J. Mol. Biol. 1999, 287:145-161.
33. Tate C.G., Schertler G.F. Engineering G protein-coupled receptors to facilitate their structure determination. Curr. Opin. Struct. Biol. 2009, 19:386-395.
34. Tate, C.G., 2009. Practical considerations of membrane protein instability for purification and crystallisation.
35. Unger T. Differences among angiotensin II type 1 receptor blockers: characteristics of candesartan cilexetil. Blood Press. 2000, (Suppl. 1):14-18.
36. Warne T., Serrano-Vega M.J., Baker J.G., Moukhametzianov R., Edwards P.C., Henderson R., Leslie A.G., Tate C.G., Schertler G.F. Structure of a b1-adrenergic G-protein-coupled receptor. Nature 2008.
37. Warne T., Serrano-Vega M.J., Tate C.G., Schertler G.F. Development and crystallization of a minimal thermostabilised G protein-coupled receptor. Protein Expr. Purif. 2009, 65:204-213.